Bayesian Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Bayesian Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20,536	Closed	-$137K	–	815
2025 Q1	$137K	Sell	20,536 -9,000	-30%	-$88.9K	0.02%	524
2024 Q4	$371K	Buy	+29,536	New	+$445K	0.05%	441
2024 Q1	–	Sell	-17,009	Closed	-$510K	–	1056
2023 Q4	$510K	Buy	+17,009	New	+$375K	0.05%	379

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Bayesian Capital Management's RCKT Position: Q2 2025 in Review

Bayesian Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 20,536 shares — an estimated $137K sold.

Bayesian Capital Management first reported a position in RCKT in Q4 2023 and held it in 3 quarters. The position peaked at $510K in Q4 2023. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

Bayesian Capital Management reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Bayesian Capital Management sold 20,536 Rocket Pharmaceuticals shares in Q2 2025, an estimated $137K.
Bayesian Capital Management first reported a position in Rocket Pharmaceuticals in Q4 2023 and held it in 3 quarters.
Bayesian Capital Management's Rocket Pharmaceuticals position peaked at $510K in Q4 2023.
196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Bayesian Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.